Aldeyra Therapeutics remains a pre-revenue biotechnology entity heavily reliant on equity-based funding to sustain its clinical development pipeline.
Price trend, volume and key moving averages
Trailing total returns as of 11/8/2026, which may include dividends or other distributions. Benchmark is S&P 500 (^GSPC).
Recent results and news deserve attention only when they alter the forward view.
| Quarter | EPS (Act vs Est) | Revenue (Act vs Est) |
|---|---|---|
Q4 2026Latest Nov 4, 2026 | -$0.06+45.5% vs -$0.11 | — vs $3M |
Q3 2026 Aug 6, 2026 | -$0.09-2.9% vs -$0.09 | — vs $31M |
Q2 2026 May 7, 2026 | -$0.06+53.8% vs -$0.13 | — vs — |
Q1 2026 Feb 27, 2026 | -$0.11+21.4% vs -$0.14 | — vs $5M |
Aldeyra Therapeutics, Inc. (NASDAQ:ALDX) shares are trading higher on Tuesday as investors react to the company's intent to submit a formal dispute resolution request tied to its reproxalap program.
Aldeyra Therapeutics, Inc. (ALDX) Discusses FDRR and FDA Review Process for Reproxalap in Dry Eye Disease Transcript
Aldeyra Therapeutics NASDAQ: ALDX said it plans to submit a formal dispute resolution request, or FDRR, to the FDA's Office of New Drugs seeking review of the agency's latest complete response letter for reproxalap, its investigational treatment for the signs and symptoms of dry eye disease.
CONCORD, Mass.--(BUSINESS WIRE)--Aldeyra Therapeutics, Inc. (Nasdaq: ALDX) (Aldeyra), a biotechnology company devoted to discovering and developing innovative therapies designed to treat immune-mediated diseases, today announced intent to submit to the U.S. Food and Drug Administration (FDA) a Formal Dispute Resolution Request (FDRR) for reproxalap, an investigational drug candidate, for the treatment of dry eye disease. The FDRR, which is expected to be reviewed by the FDA's Office of New Drug.
Benchmark ALDX against direct peers instead of judging its metrics in isolation.
Key metrics vs top competitors for Aldeyra The (ALDX)
| Company | Price | Market Cap | P/E Ratio | Rev Growth (1Y) | Net Margin | ROE | Div Yield |
|---|---|---|---|---|---|---|---|
| $0.63 | $38.23M | — | — | — | -42.73% | — | |
| $6.60 | $1.45B | -4.93 | -18.67% | -579.1% | -59.87% | — | |
| $0.16 | $11.56K | -0.00 | — | — | -222.32% | — | |
| $103.63 | $12.29B | 26.18 | 37.55% | 26.93% | 544.26% | — | |
| $46.94 | $5.62B | -15.01 | — | — | -160.19% | — | |
| $277.62 | $7.74B | -23.85 | -100% | — | -34.15% | — |
Aldeyra The (ALDX) vs competitors — business, growth, and fundamentals comparison against the closest industry rivals.
Verify the primary filings, follow material updates, and answer the remaining questions.
Aldeyra The (ALDX) SEC filings — annual & quarterly reports (10-K, 10-Q)
Jul 30, 2026·SEC
Jul 15, 2026·SEC
Jun 10, 2026·SEC
Get notified when ALDX posts new earnings or crosses analyst targets
Free. No account needed. Unsubscribe any time.
Aldeyra The (ALDX) stock FAQ — growth, dividends, profitability & financials explained
No. Aldeyra The (ALDX) reported a net loss of $3.76T over the trailing twelve months.
Aldeyra The (ALDX) had a return on equity (ROE) of -42.7% over the trailing twelve months. A negative ROE means the company lost money over the period.
Aldeyra The (ALDX) had negative free cash flow of $13.82T over the trailing twelve months.
